Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Spotlight on double and triple enzyme inhibitors for treating cardiovascular disease

Feb. 24, 1999

Tissue factor inhibition: another mechanism linked to the cardiovascular effects of resveratrol

Feb. 23, 1999

Trial results of rhVEGF165 in CAD disappointing

Feb. 23, 1999

AVI BioPharma presents data from preclinical study of Resten-NG in restenosis

Feb. 22, 1999

Renal protective effects of azelnidipine involve inhibition of AGE production

Feb. 22, 1999

Antihypertensive effects of bradykinin agonist FR-190997 evaluated in animals

Feb. 22, 1999

Novel antihypertensive drug candidate available for licensing from VUFB

Feb. 19, 1999

Amlodipine not associated with adverse arrhythmic events in CAD patients

Feb. 18, 1999

Patent covers new ADIR compounds with high affinity for imidazoline receptors

Feb. 18, 1999

New vasopeptidase inhibitor advances in clinical trials at Bristol-Myers Squibb

Feb. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...